Toll-like receptor modulators: A patent review (2006 - 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 6, 2011, Pages 927-944

  Basith, Shaherin ^a   Manavalan, Balachandran ^a   Lee, Gwang ^a,b   Kim, Sang Geon ^c   Choi, Sangdun ^a  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

agonist; antagonist; clinical trial; immunomodulator; infection; inflammation; innate immunity; pathogen recognition receptor; toll like receptor

Indexed keywords

1 A 6; 852 A; AGATOLIMOD; AMP 516; ANA 773; ANA 975; AVE 0675; AZD 8848; CBLB 502; CPG 52364; CPN 10; DIMS 0150; ERITORAN; HELPSAV; HEPATITIS B VACCINE; IBUDILAST; IMIQUIMOD; IMMUNOMODULATING AGENT; IMO 2055; IMO 2125; IMO 2134; IMO 3100; IPH 3102; IRS 954; ISS 1018; MGN 1703; MGN 1706; NI 0101; NUTHRAX; OM 174; OPN 305; OPN 401; POLLINEX QUATTRO; RESATORVID; RESIQUIMOD; RINTATOLIMOD; SAR 21609; SD 101; SMP 105; STIMUVAX; TOLL LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAX 102; VTX 1463; VTX 2337; WART VIRUS VACCINE;

ACUTE RADIATION SYNDROME; ALLERGIC RHINITIS; ALLERGY; ANTHRAX; ASTHMA; BLADDER CANCER; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; HEPATITIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION; INFLAMMATION; INNATE IMMUNITY; ISCHEMIA; LUNG CARCINOMA; LYMPHOMA; MELANOMA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PATENT; PROSTATE CANCER; REVIEW; SKIN CANCER; SOLID TUMOR; T CELL LYMPHOMA; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; VIRUS INFECTION;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; PATENTS AS TOPIC; TOLL-LIKE RECEPTORS;

EID: 79956188587     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.569494     Document Type: Review

References (125)

1. Sansonetti PJ. The innate signaling of dangers and the dangers of innate signaling. Nat Immunol 2006;7:1237-42 (Pubitemid 46111240)
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801 (Pubitemid 43261452)
3. Hoebe K, Jiang Z, Georgel P, et al. TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy. Curr Pharm Des 2006;12:4123-34 (Pubitemid 44669741)
4. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7 (Pubitemid 27334820)
5. Poltorak A, Smirnova I, He X, et al. Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 1998;24:340-55 (Pubitemid 28524834)
6. Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998;95:588-93 (Pubitemid 28083787)
7. Roach JC, Glusman G, Rowen L, et al. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 2005;102:9577-82 (Pubitemid 40981723)
8. Rast JP, Smith LC, Loza-Coll M, et al. Genomic insights into the immune system of the sea urchin. Science 2006;314:952-6 (Pubitemid 44749931)
9. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-84
10. O?Neill LA, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003;24:286-90
11. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35 (Pubitemid 44631651)
12. Hennessy EJ, Parker AE, O?Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010;9:293-307
13. Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458:1191-5
14. Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008;320:379-81 (Pubitemid 351555661)
15. Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007;130:1071-82 (Pubitemid 47410281)
16. Krishnan J, Selvarajoo K, Tsuchiya M, et al. Toll-like receptor signal transduction. Exp Mol Med 2007;39:421-38 (Pubitemid 47443856)
17. Zhu J, Brownlie R, Liu Q, et al. Characterization of bovine Toll-like receptor 8: ligand specificity, signaling essential sites and dimerization. Mol Immunol 2009;46:978-90
18. Honda K, Yanai H, Mizutani T, et al. Role of a transductional- transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA 2004;101:15416-21 (Pubitemid 39441556)
19. Kawai T, Sato S, Ishii KJ, et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004;5:1061-8 (Pubitemid 41057726)
20. Pandey S, Agrawal DK. Immunobiology of Toll-like receptors: emerging trends. Immunol Cell Biol 2006;84:333-41 (Pubitemid 43882838)
21. Krishnan J, Lee G, Choi S. Drugs targeting Toll-like receptors. Arch Pharm Res 2009;32:1485-502
22. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 2007;12:80-7 (Pubitemid 46014484)
23. Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007;35:1461-7
24. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9 (Pubitemid 46830615)
25. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008;65:3231-40
26. Hughes AL, Piontkivska H. Functional diversification of the toll-like receptor gene family. Immunogenetics 2008;60:249-56
27. Underhill DM, Ozinsky A, Hajjar AM, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999;401:811-15
28. Aliprantis AO, Yang RB, Mark MR, et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999;285:736-9
29. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-6
30. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19:3-10 (Pubitemid 46498750)
31. Tapping RI. Innate immune sensing and activation of cell surface Toll-like receptors. Semin Immunol 2009;21:175-84
32. Eriksson EM, Jackson DC. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci 2007;8:412-17 (Pubitemid 47317044)
33. Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem 2008;15:506-16 (Pubitemid 351472417)
34. Gallorini S, Berti F, Mancuso G, et al. Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides. Proc Natl Acad Sci USA 2009;106:17481-6
35. Liang S, Hosur KB, Nawar HF, et al. In vivo and in vitro adjuvant activities of the B subunit of Type 2b heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli. Vaccine 2009;27:4302-8
36. Liu X, Wetzler LM, Massari P. The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant. Vaccine 2008;26:786-96
37. Simons MP, O?Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008;26:341-5 (Pubitemid 351885380)
38. Murata M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 2008;99:1435-40 (Pubitemid 351761735)
39. Guan Y, Omueti-Ayoade K, Mutha SK, et al. Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening. J Biol Chem 2010;285:23755-62
40. Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000;164:5998-6004 (Pubitemid 30389848)
41. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002;168:554-61 (Pubitemid 34049553)
42. Sugiyama T, Hoshino K, Saito M, et al. Immunoadjuvant effects of polyadenylic: polyuridylic acids through TLR3 and TLR7. Int Immunol 2008;20:1-9
43. Salaun B, Coste I, Rissoan MC, et al. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-901
44. Panter G, Kuznik A, Jerala R. Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr Opin Mol Ther 2009;11:133-45
45. Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27:3401-4
46. Rudd BD, Burstein E, Duckett CS, et al. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 2005;79:3350-7 (Pubitemid 40327923)
47. Choe J, Kelker MS, Wilson IA. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 2005;309:581-5 (Pubitemid 41033635)
48. Salem ML, El-Naggar SA, Kadima A, et al. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 2006;24:5119-32 (Pubitemid 43818196)
49. Tewari K, Flynn BJ, Boscardin SB, et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010;28:7256-66
50. Zheng R, Cohen PA, Paustian CA, et al. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 2008;68:4045-9
51. Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009;206:1589-602
52. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003;15:5-11 (Pubitemid 35454185)
53. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316:1628-32 (Pubitemid 46982038)
54. Krieg AM. Toll-free vaccines? Nat Biotechnol 2007;25:303-5 (Pubitemid 46398765)
55. D?souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56 (Pubitemid 46740304)
56. D?Agostini C, Pica F, Febbraro G, et al. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol 2005;5:1205-12 (Pubitemid 40725714)
57. De Ridder M, Verovski VN, Chiavaroli C, et al. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase. Int J Radiat Oncol Biol Phys 2006;66:1473-80
58. Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006;5:617-29 (Pubitemid 46021044)
59. Baldrick P, Richardson D, Woroniecki SR, Lees B. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. J Appl Toxicol 2007;27:399-409 (Pubitemid 47066769)
60. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81 (Pubitemid 46190262)
61. Andersen-Nissen E, Smith KD, Bonneau R, et al. A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin. J Exp Med 2007;204:393-403 (Pubitemid 46294554)
62. Huleatt JW, Nakaar V, Desai P, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008;26:201-14 (Pubitemid 50008089)
63. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320:226-30 (Pubitemid 351521417)
64. O?Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009;61:177-97
65. Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008;27:181-9
66. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-9
67. Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 2008;21:69-87 (Pubitemid 351628232)
68. Harrison LI, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 2007;47:962-9 (Pubitemid 47094102)
69. Dummer R, Hauschild A, Becker JC, et al. An exploratory study of systemic administration of the toll-like receptor- 7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008;14:856-64 (Pubitemid 351231170)
70. Pockros PJ, Guyader D, Patton H, et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007;47:174-82 (Pubitemid 47021257)
71. Lee J, Wu CC, Lee KJ, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 2006;103:1828-33 (Pubitemid 43228778)
72. Fletcher S, Steffy K, Averett D. Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease. Curr Opin Investig Drugs 2006;7:702-8 (Pubitemid 44263174)
73. Kronenberger B, Zeuzem S. Current and future treatment options for HCV. Ann Hepatol 2009;8:103-12
74. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5 (Pubitemid 32015992)
75. Airapetian A, Akopov N, Akopov Z, et al. Flavor decomposition of the sea-quark helicity distributions in the nucleon from semiinclusive deep inelastic scattering. Phys Rev Lett 2004;92:012005
76. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009;61:195-204
77. Goodchild A, Nopper N, Craddock A, et al. Primary leukocyte screens for innate immune agonists. J Biomol Screen 2009;14:723-30
78. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161-7
79. Harandi AM, Davies G, Olesen OF. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 2009;8:293-8
80. Friedberg JW, Kelly JL, Neuberg D, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009;146:282-91
81. Kochling J, Prada J, Bahrami M, et al. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 2008;26:4669-75
82. Dorn A, Kippenberger S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr Opin Mol Ther 2008;10:10-20 (Pubitemid 351170590)
83. Heijink IH, Van Oosterhout AJ. Strategies for targeting T-cells in allergic diseases and asthma. Pharmacol Ther 2006;112:489-500 (Pubitemid 44486416)
84. Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21
85. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005;115:3149-56 (Pubitemid 41567579)
86. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003;23:15-44 (Pubitemid 36875472)
87. Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9 (Pubitemid 41464506)
88. Asagiri M, Hirai T, Kunigami T, et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008;319:624-7 (Pubitemid 351197065)
89. Rodriguez D, Keller AC, Faquim-Mauro EL, et al. Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity. J Immunol 2003;171:1001-8 (Pubitemid 36871416)
90. Liu X, Ukai T, Yumoto H, et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2008;196:146-54
91. Rezaei N. Therapeutic targeting of pattern-recognition receptors. Int Immunopharmacol 2006;6:863-9
92. Gearing AJ. Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol Cell Biol 2007;85:490-4 (Pubitemid 47367512)
93. Meng G, Rutz M, Schiemann M, et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004;113:1473-81 (Pubitemid 39071703)
94. Arslan F, de Kleijn DP, Timmers L, et al. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr Pharm Des 2008;14:1205-16 (Pubitemid 351997833)
95. Chang YC, Kao WC, Wang WY, et al. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB J 2009;23:3078-88
96. Spiller S, Elson G, Ferstl R, et al. TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med 2008;205:1747-54
97. Bennett-Guerrero E, Grocott HP, Levy JH, et al. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2007;104:378-83
98. Vanags D, Williams B, Johnson B, et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006;368:855-63 (Pubitemid 44292809)
99. Broadley SA, Vanags D, Williams B, et al. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult Scler 2009;15:329-36
100. Ii M, Matsunaga N, Hazeki K, et al. A novel cyclohexene derivative, ethyl (6R)-6-N-(2-Chloro-4-fluorophenyl) sulfamoyl.cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 2006;69:1288-95
101. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007;16:935-50 (Pubitemid 47078775)
102. Ungaro R, Fukata M, Hsu D, et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G1167-79
103. Vollmer J, Tluk S, Schmitz C, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005;202:1575-85 (Pubitemid 41746603)
104. Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417-28 (Pubitemid 44354217)
105. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type 1 interferons. Curr Opin Immunol 2006;18:676-82 (Pubitemid 44635182)
106. Barrat FJ, Meeker T, Chan JH, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007;37:3582-6
107. Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007;18:1721-31 (Pubitemid 46870309)
108. Parkinson T. The future of toll-like receptor therapeutics. Curr Opin Mol Ther 2008;10:21-31 (Pubitemid 351170591)
109. Manavalan B, Govindaraj R, Lee G, Choi S. Molecular modeling-based evaluation of dual function of IkappaBzeta ankyrin repeat domain in toll-like receptor signaling. J Mol Recognit 2010. [Epub ahead of print]
110. Govindaraj RG, Manavalan B, Lee G, Choi S. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in Toll-like receptor signaling. PLoS One 2010;5:e12713
111. Manavalan B, Basith S, Choi YM, et al. Structure-Function Relationship of Cytoplasmic and Nuclear IkappaB Proteins: an in silico analysis. PLoS One 2010;5:e15782
112. Sheedy FJ, O?Neill LA. Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann Rheum Dis 2008;67(Suppl 3):iii50-5
113. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006;311:1-16 (Pubitemid 47413193)
114. Ishii KJ, Gursel I, Gursel M, Klinman DM. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr Opin Mol Ther 2004;6:166-74
115. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776-87
116. Lee HK, Brown SJ, Rosen H, Tobias PS. Application of beta-lactamase enzyme complementation to the high-throughput screening of toll-like receptor signaling inhibitors. Mol Pharmacol 2007;72:868-75 (Pubitemid 47481410)
117. Toshchakov VY, Fenton MJ, Vogel SN. Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs. J Immunol 2007;178:2655-60 (Pubitemid 46333141)
118. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004;140:1490-5 (Pubitemid 39627441)
119. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-9 (Pubitemid 38314424)
120. Gorden KK, Qiu XX, Binsfeld CC, et al. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 2006;177:6584-7 (Pubitemid 44715019)
121. Uenishi Y, Kawabe K, Nomura T, et al. Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105). J Microbiol Methods 2009;77:139-44
122. Makkouk A, Abdelnoor AM. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol Immunotoxicol 2009;31:331-8
123. Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect 2008;21:434-9
124. Wasan KM, Risovic V, Sivak O, et al. Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits. Pharm Res 2008;25:176-82
125. Ledeboer A, Liu T, Shumilla JA, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 2006;2:279-91 (Pubitemid 47074741)